For years, mainstream medicine and popular diet gurus have promoted the ketogenic diet as a “cancer-fighting” strategy. The logic seems simple: cancer cells consume glucose, so if you eliminate carbohydrates and force the body to burn fat, you will starve the tumor. For years, Ray argued the opposite: prolonged reliance on fatty acid oxidation is tumorigenic, and high-fat diets promote cancer even in the absence of obesity. The study below, published in Cancer & Metabolism, directly validates our position. The researchers show that hyperlipidemia (elevated blood lipids) is sufficient to accelerate breast cancer growth irrespective of adiposity, blood glucose, or insulin levels. A ketogenic diet promoted tumor growth even in lean animals, and weight loss alone — without lowering blood lipids — failed to protect against cancer. This study corroborates several key points of the bioenergetic theory: (1) it is healthier to oxidize primarily carbohydrates, not fat; (2) hyperlipidemia, not obesity per se, is the driver of cancer; and (3) high-fat diets are detrimental even for lean individuals whom doctors consider “healthy.”
As the study below demonstrates, researchers using orthotopic mouse models of breast cancer found that elevated circulating lipids are sufficient to accelerate tumor growth even in the absence of obesity or alterations in blood glucose and/or insulin levels. In genetic models of hyperlipidemia (ApoE KO and LDLR KO mice), tumors grew two to three times larger than in wild-type controls, despite the hyperlipidemic mice being leaner and having normal glucose and insulin. In a ketogenic diet (90% fat) model, mice developed significant hyperlipidemia (triglycerides 3.5 times higher, cholesterol 2.5 times higher) with no difference in insulin or glucose. E0771 tumors were twice as large in KD-fed mice compared to low-fat diet controls.
Critically, when the researchers used a pharmacological lipid-lowering agent (antisense oligonucleotide targeting Angptl3), they reversed the tumor-promoting effect without changing adiposity. Obese mice treated with the lipid-lowering drug had tumors 1.6 times smaller than untreated obese controls, despite identical body weight and fat mass. Even more striking: weight loss alone did not protect against cancer if hyperlipidemia persisted. Obese mice switched to a ketogenic diet lost weight and normalized glucose and insulin, but maintained elevated lipids — and their tumor growth was not significantly different from obese mice that remained on the high-fat diet.
This study directly validates four core principles of the bioenergetic view:
-
It is preferable to oxidize carbohydrates, not fat. The ketogenic diet promoted tumor growth despite weight loss and normalized glucose. Forcing the body to rely on fatty acid oxidation is tumorigenic.
-
Hyperlipidemia, not obesity or high glucose diets, is the main driver of cancer. A lean person on a high-fat diet can have low body fat but high circulating lipids — and thus higher cancer risk — than an obese person using lipolysis-lowering agents.
-
Weight loss without lipid lowering is insufficient. This explains why many people who lose weight on ketogenic diets do not see cancer protection; the persistent hyperlipidemia continues to fuel tumor growth.
-
The interventions we recommend — niacinamide (lowers free fatty acids via adiponectin), aspirin (lowers FFA via inhibition of lipolysis), and vitamin E (prevents lipid peroxidation) — directly target the pathological hyperlipidemia identified in this study. These agents lower blood lipids without requiring weight loss.
The human-equivalent doses are not directly applicable from this mouse study, but the principles are clear: monitor blood lipids (triglycerides, cholesterol, NEFA), keep them low, and avoid high-fat diets even if they cause weight loss. The study’s ketogenic diet was 90% fat by calories — similar to many popular “keto” diets. The authors explicitly state that “health nutrition plans as adjuvant therapies for cancer need to account for the lipid dependencies of cancer cells.”
https://link.springer.com/article/10.1186/s40170-025-00407-0
“…Using both dietary and genetic mouse models, we show that elevated circulating lipids are sufficient to accelerate BC tumor growth even in the absence of obesity or alterations in blood glucose and/or insulin levels.”
“…Pharmacological lowering of systemic lipid levels attenuates BC growth in obese mice, suggesting a direct role for lipids in fueling tumor expansion.”
“…Weight loss alone, without a corresponding reduction in lipid levels such as that induced by a ketogenic diet, fails to protect against BC , highlighting the necessity of targeting lipid metabolism in obesity-associated BC.”
“…Our findings establish hyperlipidemia as a critical driver of BC progression and suggest that lipid-lowering interventions may be a promising strategy to mitigate BC risk in individuals with obesity.”
“…E0771 tumors were twice as large in KD mice (90% fat ketogenic diet) compared to LFD-fed controls, despite normal insulin and glucose levels.”
“…In ApoE KO and LDLR KO mice (genetic hyperlipidemia), E0771 tumors were two to three times larger than in wild-type controls, despite the hyperlipidemic mice being significantly leaner.”
“…Angptl3-ASO treatment (lipid-lowering) reduced tumor mass by 1.6-fold in obese mice without affecting body weight or adiposity.”
“…Mice switched to a ketogenic diet for weight loss maintained elevated triglycerides, cholesterol, and NEFA levels… E0771 tumor growth was not significantly different than in obese mice maintained on high-fat diet, despite being significantly leaner.”
“…We propose that health nutrition plans as adjuvant therapies for cancer need to account for the lipid dependencies of cancer cells in the context of an individual’s metabolic health.”
